The trial program has evolved from glycemic-safety and outcomes studies in T2D (the LEADER, SUSTAIN-6, REWIND, EXSCEL, and PIONEER 6 era [10][13], [19]), to outcomes trials in expanded populations including obesity without diabetes (SELECT [3]), HFpEF with obesity (SUMMIT [5], with a companion semaglutide program in STEP-HFpEF [20], [21]), CKD (FLOW [22]), and an active-comparator setting (SURPASS-CVOT [6])
Similar criteria apply across England (NHSBT), Scotland (SNBTS), and Wales (Welsh Blood Service)
The pill works through the same mechanism as the injection
Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin
The combination of semaglutide and regular alcohol may accelerate liver fat accumulation in susceptible individuals, though research is still emerging